Clinical Strategies for Enhancing the Efficacy of CAR T-Cell Therapy for Hematological Malignancies.

ABSTRACT: Chimeric antigen receptor (CAR) T cells have been successfully used for hematological malignancies, especially for relapsed/refractory B-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Patients who have undergone conventional chemo-immunotherapy and have relapsed can achieve complete remission for several months with the infusion of CAR T-cells. However, side effects and short duration of response are still major barriers to further CAR T-cell therapy. To improve the efficacy, multiple targets, the discovery of new target antigens, and CAR T-cell optimization have been extensively studied. Nevertheless, the fact that the determination of the efficacy of CAR T-cell therapy is inseparable from the discussion of clinical application strategies has rarely been discussed. In this

SUBMITTER: Liu Q 

PROVIDER: S-EPMC9496667 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature